Users Discontinuing Slimming Medications Gain Back Weight Far More Rapidly Compared to People Using Diet and Exercise

A recent study suggests that patients who stop using blockbuster GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds much more quickly than those who end traditional diet and exercise programs.

Published data in a major health publication demonstrates that while obese individuals can lose a large proportion of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.

"Users using such drugs need to be informed of the danger of quick rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.

That rate of regain suggests a reversion to pre-treatment weight within about 18 months.

Weighing Treatments

The study, which reviewed 37 of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with other pills.

The team note that people who shed pounds through lifestyle changes alone generally have a slower weight regain—perhaps 0.1 kg a month—post-intervention.

Explaining the Rapid Rebound

Nutrition scientists believe the way of the drugs is key to understanding the accelerated regain.

GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate appetite.

"Long-term administration of the hormone levels far above than the body's typical production could lead to the body to produce less of its own natural hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.

"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making binge eating a significant risk."

A Lifelong Disease?

The NHS recommend the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.

Many experts argue that, considering the likelihood of relapse, the treatment is often life-long.

This opinion is supported by pharmaceutical companies, who state that the results "underscore the persistent character of obesity," comparing it to managing diseases like diabetes.

Patient Accounts

Users who have stopped the jabs explain a powerful return of appetite.

"It felt as if a trigger activating and I was suddenly starving," recalled an individual.

This difficulty is compounded if patients have not adopted permanent lifestyle or habit modifications during treatment.

Significant Interest

Figures suggest that millions of adults in the UK have used these injections in the last 12 months, with interest being substantial.

• Use is more common among females compared to males.
• The middle-aged age group shows the highest usage rates.
• A large proportion obtain the medications through private healthcare rather than public health services.

In conclusion, clinicians stress that while GLP-1 drugs are effective agents for weight loss, they are not a permanent solution and long-term success relies on combined lifestyle management.